Immunotherapy duo takes aim at tough pancreatic cancer before surgery

NCT ID NCT06060405

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether giving two immunotherapy drugs, durvalumab and oleclumab, before surgery can boost the immune system's attack on pancreatic cancer. The study involves people with resectable pancreatic ductal adenocarcinoma (PDAC) who will receive the drugs in a short window before their tumor is removed. Researchers will measure changes in immune cells within the tumor to see if the treatment enhances the body's natural defenses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab and oleclumab
What this could lead to: If successful, this approach could improve immune response against pancreatic cancer, potentially leading to better outcomes after surgery.
What could go wrong: This is a small, early-phase study focused on immune markers, not survival. The drugs may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.